Our timing into Isolagen (ILE) has sure been bad and the stock remains one of our worst performers. However, we still remain optimistic about this biotech over a 3-year time horizon, even if the prospects of additional financing actions may put pressure on the stock for some time. In this post, we’ll update you on some of the more important events related to the Isolagen (ILE) situation.

We think that Isolagen (ILE), an early-stage biotechnology company focused on the skincare market, offers investors an extraordinary opportunity to invest alongside a proven management team with significant experience in Isolagen’s core market.